NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
AstraZeneca
I-Mab Biopharma US Limited
City of Hope Medical Center
Sotio Biotech Inc.
Alaunos Therapeutics
Incyte Corporation
Elicio Therapeutics
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Institut Bergonié
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
University of Pennsylvania
NextCure, Inc.
National Institutes of Health Clinical Center (CC)
Elevation Oncology
Stanford University
Deciphera Pharmaceuticals, LLC
Sellas Life Sciences Group
NantCell, Inc.
NantCell, Inc.
Pfizer
ADC Therapeutics S.A.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Pfizer
Memorial Sloan Kettering Cancer Center
Pfizer
CytomX Therapeutics
pharmaand GmbH
Canadian Cancer Trials Group
Hoffmann-La Roche
OncoNano Medicine, Inc.
Revolution Medicines, Inc.
Herlev Hospital
Incyte Corporation
Duke University
Five Prime Therapeutics, Inc.
Incyte Corporation
Seagen Inc.
Incyte Corporation
Seagen Inc.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Institutes of Health Clinical Center (CC)
Pfizer
PharmaMar